Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4986011 | 0.93 | SIGMAR1 (0.50) | MEN1KMT2ANPSR1SIGMAR1KCNH2 | |
| SCHEMBL4988311 | 0.91 | SIGMAR1 (0.42) | SIGMAR1KCNH2GBA1TDP1 | |
| SCHEMBL4981472 | 0.84 | SIGMAR1 (0.47) | MEN1KMT2ASIGMAR1KCNH2MAPT | |
| SCHEMBL4455539 | 0.82 | SIGMAR1 (0.48) | SIGMAR1KCNH2GBA1OPRM1DRD3 | |
| SCHEMBL4986079 | 0.81 | SIGMAR1 (0.43) | SIGMAR1KCNH2GBA1TDP1 | |
| SCHEMBL23112462 | 0.77 | SIGMAR1 (0.45) | SIGMAR1KCNH2MAPTKDM4EGBA1 | |
| SCHEMBL4851319 | 0.76 | SLC2A1 (0.50) | KDM4E | |
| SCHEMBL22570767 | 0.76 | SLC2A1 (0.50) | KDM4E | |
| SCHEMBL453579 | 0.76 | SLC2A1 (0.50) | KDM4E | |
| SCHEMBL27287382 | 0.75 | KCNH2 (0.58) | SIGMAR1KCNH2OPRM1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2966054-B1 | METHOD OF PRODUCING OPTICALLY-ACTIVE ALDEHYDE | TAKASAGO PERFUMERY CO LTD (JP) | 2019-01-02 | — | — | EP | disclosed |
| US-10029969-B2 | Method of producing optically-active aldehyde | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| EP-2966054-A1 | METHOD OF PRODUCING OPTICALLY-ACTIVE ALDEHYDE | Takasago International Corporation (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-20150376102-A1 | METHOD OF PRODUCING OPTICALLY-ACTIVE ALDEHYDE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150329452-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ISOPULEGOL AND OPTICALLY ACTIVE MENTHOL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-2921228-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ISOPULEGOL AND OPTICALLY ACTIVE MENTHOL | Takasago International Corporation (JP) | 2015-09-23 | — | — | EP | disclosed |
| US-7393958-B2 | Triamide-substituted heterobicyclic compounds | PFIZER, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7368573-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2007-04-26 | — | — | US | disclosed |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | BERTINATO PETER | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329452-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ISOPULEGOL AND OPTICALLY ACTIVE MENTHOL | ACSL3, ACSL6, ALOX5 | MEN1 481/4885KMT2A 2214/4885NPSR1 2618/4885 |
| US-10029969-B2 | Method of producing optically-active aldehyde | ALDH3A1, ALDH1A2, ADH1A | MEN1 3945/4885KMT2A 3097/4885NPSR1 3703/4885 |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | APOB, MTPN, CTRB1 | MEN1 1637/4885KMT2A 4384/4885NPSR1 348/4885 |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | APOB, MTPN, CTRB1 | MEN1 1637/4885KMT2A 4384/4885NPSR1 348/4885 |
| US-20150376102-A1 | METHOD OF PRODUCING OPTICALLY-ACTIVE ALDEHYDE | ALDH3A1, ALDH1A2, ADH1A | MEN1 3945/4885KMT2A 3097/4885NPSR1 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.